Skip to main content
Premium Trial:

Request an Annual Quote

BioDiscovery, N-of-One Ink Marketing Deal for Genomic Analysis Solutions

NEW YORK (GenomeWeb News) – BioDiscovery and N-of-One today announced a marketing agreement to provide genomic analysis interpretation solutions.

The companies will jointly market and sell N-of-One's interpretation solutions and content with BioDiscovery's genomic analysis software. The deal, they said, will allow clinicians to use genomic data more easily and efficiently to identify targeted therapies that are most appropriate for each individual patient and to better understand the molecular profile of the patient's tumor.

Financial and other terms of the deal were not disclosed.

In a statement N-of-One CEO Chris Cournoyer said the agreement "gives oncologists and treating clinicians additional insights into possible therapeutic strategies that are informed by the patient's disease, genomic profile, available therapies and trials, and current research."

Today's deal follows an agreement last month between N-of-One and Appistry to provide sequence data analysis and molecular interpretation services.